ReviewDigestive diseases and sciences2012
Advances in the current treatment of autoimmune hepatitis.
Review in Digestive diseases and sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01661842 (Phase 1/2 Study of UC-MSC Treatment for Evaluation the Efficacy and Safety in Patients With Autoimmune Liver Disease), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1/2 Study of UC-MSC Treatment for Evaluation the Efficacy and Safety in Patients With Autoimmune Liver Disease
Who cites it
16 citing papers in PubMed, 45 citations in OpenAlex.
- Pathogens and autoimmune hepatitis.Clinical and experimental immunology · 2019Review
- Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.Digestive diseases and sciences · 2018Article
- [Standard treatment of autoimmune hepatitis: experience from rheumatoid arthritis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Autoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease?Frontiers in immunology · 2018Review
- Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis.Digestive diseases and sciences · 2017Observational
- Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models?International journal of molecular sciences · 2016Review
- Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients.Hepatology international · 2016Article
- Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children.Przeglad gastroenterologiczny · 2016Article
- Autoimmune Hepatitis in Hawai'i.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2015Article
- Management of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroids.World journal of hepatology · 2014Review
- Autoimmune Hepatitis: Clinical Review with Insights into the Purinergic Mechanism of Disease.Journal of clinical and translational hepatology · 2013Review
- Challenges in the diagnosis and management of autoimmune hepatitis.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Review
- Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.Digestive diseases and sciences · 2013Review
- Acute and acute severe (fulminant) autoimmune hepatitis.Digestive diseases and sciences · 2013Review
- The overlap syndromes of autoimmune hepatitis.Digestive diseases and sciences · 2013Review
- Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.Autoimmune diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current treatment strategies for autoimmune hepatitis are complicated by frequent relapse after drug withdrawal, medication intolerance, and refractory disease. The objective of this review is to describe advances that have improved treatment outcomes by defining the optimum objectives of initial therapy, managing relapse more effectively, identifying problematic patients early, and incorporating the new pharmacological interventions that have emerged as frontline and salvage therapies. Initial corticosteroid treatment should be continued until serum aminotransferase, γ-globulin, and immunoglobulin G levels are normal, and maintenance of this improvement for 3-8 months before liver tissue assessment. Improvement to normal liver tissue is the ideal histological result that justifies drug withdrawal, but it is achievable in only 22 % of patients. Minimum portal hepatitis, inactive cirrhosis, or minimally active cirrhosis is the most common treatment end point. Relapse after drug withdrawal warrants institution of a long-term maintenance regimen, preferably with azathioprine. Mathematical models can identify problematic adult patients early, as also can clinical phenotype (age ≤ 30 years and HLA DRB1 03), rapidity of treatment response (≤ 24 months), presence of antibodies to soluble liver antigen, and non-white ethnicity. The calcineurin inhibitors (cyclosporine and tacrolimus) can be effective in steroid-refractory disease; mycophenolate mofetil can be corticosteroid-sparing and effective for azathioprine intolerance; budesonide combined with azathioprine can be effective for treatment-naïve, non-cirrhotic patients. Standard treatment regimens for autoimmune hepatitis can be upgraded without adjustments that require major new expertise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.